Managed Access Programme – an update
The recent publication by NICE of a ‘Minded Yes’ recommendation for elosulfase alfa (VIMIZIM®▼) is contingent upon all stakeholders agreeing to a Managed Access programme for patients. BioMarin has been working with all stakeholders towards this end. Progress is being made towards a workable solution that would allow eligible MPS IVA patients in England to receive treatment. Whilst discussions are ongoing, BioMarin has agreed to continue providing VIMIZIM®▼ to patients already receiving treatment under the established financial support programme. This commitment will remain in place provided the Managed Access programme is agreed and implemented. The anticipated date for this is late December 2015 or early January 2016.